{"id":3904,"date":"2025-03-31T18:11:52","date_gmt":"2025-03-31T18:11:52","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/desirudin-txt\/"},"modified":"2025-03-31T18:11:52","modified_gmt":"2025-03-31T18:11:52","slug":"desirudin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/desirudin-txt\/","title":{"rendered":"Desirudin.txt"},"content":{"rendered":"

Desirudin<\/h1>\n

CLINICAL USE <\/H3>
\nProphylaxis of DVT in patients undergoing orthopaedic surgery

DOSE IN NORMAL RENAL FUNCTION <\/H3>15 mg 5\u201315 minutes before surgery then 15 mg twice daily for 9\u201312 days or until mobile

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :6963.4<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 40\u201350<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.25<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>31\u201360 Initially 5 mg twice daily. Aim for APTT <0.85 seconds<31 Initially 1.7 mg twice daily and monitor APTT

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR<31 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR<31 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR<31 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR<31 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAnticoagulants, antiplatelets, fondaparinux, NSAIDs, heparin and dextran \u2013 increased risk of bleeding

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>With diluent supplied

    Route <\/H4>SC

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>The effect is poorly reversible APTT levels can be reduced by IV DDAVP Available on a named patient basis from Aventis Pharma7% of dose is metabolised by the kidneys
    \n","protected":false},"excerpt":{"rendered":"

    Desirudin CLINICAL USE Prophylaxis of DVT in patients undergoing orthopaedic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3904","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3904"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3904\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}